| A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma F Saad, DM Gleason, R Murray, S Tchekmedyian, P Venner, L Lacombe, ... Journal of the National Cancer Institute 94 (19), 1458-1468, 2002 | 2093 | 2002 |
| Combination chemotherapy in advanced adrenocortical carcinoma M Fassnacht, M Terzolo, B Allolio, E Baudin, H Haak, A Berruti, S Welin, ... New England Journal of Medicine 366 (23), 2189-2197, 2012 | 888 | 2012 |
| Adjuvant mitotane treatment for adrenocortical carcinoma M Terzolo, A Angeli, M Fassnacht, F Daffara, L Tauchmanova, PA Conton, ... New England Journal of Medicine 356 (23), 2372-2380, 2007 | 864 | 2007 |
| Prevalence of adrenal incidentaloma in a contemporary computerized tomography series S Bovio, A Cataldi, G Reimondo, P Sperone, S Novello, A Berruti, ... Journal of endocrinological investigation 29, 298-302, 2006 | 856 | 2006 |
| Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up S Filetti, C Durante, D Hartl, S Leboulleux, LD Locati, K Newbold, ... Annals of Oncology 30 (12), 1856-1883, 2019 | 810 | 2019 |
| European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study … M Fassnacht, OM Dekkers, T Else, E Baudin, A Berruti, RR De Krijger, ... European journal of endocrinology 179 (4), G1-G46, 2018 | 732 | 2018 |
| Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up M Pavel, K Öberg, M Falconi, EP Krenning, A Sundin, A Perren, A Berruti, ... Annals of Oncology 31 (7), 844-860, 2020 | 697 | 2020 |
| Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A Berruti, E Baudin, H Gelderblom, HR Haak, F Porpiglia, M Fassnacht, ... Annals of oncology 23, vii131-vii138, 2012 | 413 | 2012 |
| Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial A Berruti, M Terzolo, P Sperone, A Pia, S Della Casa, DJ Gross, ... Endocrine-related cancer 12 (3), 657-666, 2005 | 392 | 2005 |
| Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone … A Berruti, L Dogliotti, C Terrone, S Cerutti, G Isaia, R Tarabuzzi, ... The Journal of urology 167 (6), 2361-2367, 2002 | 359 | 2002 |
| Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study M Fassnacht, A Berruti, E Baudin, MJ Demeure, J Gilbert, H Haak, ... The lancet oncology 16 (4), 426-435, 2015 | 348 | 2015 |
| Hypoxia-inducible factor-1α expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer D Generali, A Berruti, MP Brizzi, L Campo, S Bonardi, S Wigfield, ... Clinical Cancer Research 12 (15), 4562-4568, 2006 | 330 | 2006 |
| Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized … A Berruti, V Amoroso, F Gallo, V Bertaglia, E Simoncini, R Pedersini, ... Journal of clinical oncology 32 (34), 3883-3891, 2014 | 274 | 2014 |
| Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up M Fassnacht, G Assie, E Baudin, G Eisenhofer, C De La Fouchardiere, ... Annals of oncology 31 (11), 1476-1490, 2020 | 264 | 2020 |
| Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers … A Berruti, L Dogliotti, R BITOSSI, G FASOLIS, G GORZEGNO, M BELLINA, ... The Journal of urology 164 (4), 1248-1253, 2000 | 263 | 2000 |
| Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer F Porpiglia, C Fiori, F Daffara, B Zaggia, E Bollito, M Volante, A Berruti, ... European urology 57 (5), 873-878, 2010 | 234 | 2010 |
| Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study R Libe, I Borget, CL Ronchi, B Zaggia, M Kroiss, T Kerkhofs, J Bertherat, ... Annals of Oncology 26 (10), 2119-2125, 2015 | 233 | 2015 |
| Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients A Bottini, D Generali, MP Brizzi, SB Fox, A Bersiga, S Bonardi, G Allevi, ... Journal of Clinical Oncology 24 (22), 3623-3628, 2006 | 229 | 2006 |
| Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial M Maio, K Lewis, L Demidov, M Mandalà, I Bondarenko, PA Ascierto, ... The Lancet Oncology 19 (4), 510-520, 2018 | 226 | 2018 |
| Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma A Berruti, M Terzolo, A Pia, A Angeli, L Dogliotti Cancer: Interdisciplinary International Journal of the American Cancer …, 1998 | 209 | 1998 |
Martin FassnachtUniversitätsklinikum WürzburgVerified email at medizin.uni-wuerzburg.de
